At a glance
- Originator Takeda
- Class Guanidines; Quinolines; Small molecules
- Mechanism of Action Sodium-hydrogen antiporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure; Ischaemic heart disorders; Myocardial infarction
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Heart-failure in Japan
- 09 Jun 2004 Preclinical trials in Congestive heart failure in Japan (unspecified route)
- 04 Mar 2003 No development reported - Preclinical for Ischaemic heart disorders in Japan (unspecified route)